Sign inJoin waitlistJoin the waitlist

Aman Buzdar

Professor, Breast Medical Oncology · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

The University of Texas System Cancer Center
1974–1975
Norwalk Hospital
1973–1974
Internal Medicine
Norwalk Hospital
1972–1973
Lutheran Hospital
1971–1972
Lakewood Hospital
1970–1971
Maryview Hospital
1969–1970
Kaukini Hospital
1968–1969
Doctor of Medicine
1963–1967

Research

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
The Lancet · 2005 · 1,752 citations
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
Journal of Clinical Oncology · 2007 · 1,316 citations
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
Journal of Clinical Oncology · 1999 · 1,072 citations

Gabriel Hortobagyi
285 papers
Vicente Valero
69 papers
GB
George Blumenschein
62 papers
RT
Richard Theriault
62 papers · 1 as a fellow
SS
Sonja Singletary
61 papers
Kelly Hunt
55 papers · 1 as a fellow
FH
Frankie Holmes
46 papers
Henry Kuerer
42 papers · 5 as a fellow
Thomas Buchholz
41 papers
FA
Frederick Ames
39 papers
MM
Marsha Mcneese
37 papers
DB
Daniel Booser
33 papers

Grants

The University of Texas MD Anderson Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $1.1M · University of Tx Md Anderson Can Ctr

Clinical trials

Long-term Anastrozole Versus Tamoxifen Treatment Effects
Principal investigator · Completed
Queen Mary University of London
2010–2017
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
Principal investigator · Completed · Phase 3
National Cancer Institute (NCI)
2007–2013
Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2002–2011
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
Principal investigator · Completed · Phase 3
M.D. Anderson Cancer Center
2001–2011